Novo Nordisk(US:NVO) Zhi Tong Cai Jing·2026-01-05 11:00Core Viewpoint - Novo Nordisk (NVO.US) announced the launch of two oral weight loss medications, Wegovy, for self-paying patients in the U.S. starting January 5, with monthly prices set at $149 for the 1.5 mg and 4 mg doses, and $299 for the higher doses of 9 mg and 25 mg [1] Pricing Strategy - The 4 mg dose price will increase to $199 per month starting April 15 [1] - The pricing strategy aims to enhance Novo Nordisk's competitive position against Eli Lilly (LLY.US) in the market [1] Regulatory Approval - The U.S. Food and Drug Administration (FDA) approved the oral medication on December 22 of the previous year, marking a significant milestone for the company [1] Product Information - The newly approved oral semaglutide tablets contain the same active ingredients as the injectable Wegovy and Ozempic, and will be marketed under the Wegovy brand [1] - Novo Nordisk has previously launched an oral semaglutide medication, Rybelsus, aimed at treating type 2 diabetes [1]